Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIB1 | Q99828 | 2/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | EPS15 | P42566 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | MC5R | P33032 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24218648 | 0.96 | CIB1 (0.44) | CIB1CD274PDCD1EPS15KLKB1 | |
| SCHEMBL24218664 | 0.95 | KLK5 (0.48) | CIB1CD274PDCD1EPS15KLKB1 | |
| SCHEMBL24218662 | 0.95 | KLK5 (0.48) | CIB1CD274PDCD1EPS15KLKB1 | |
| SCHEMBL24218649 | 0.95 | KLK5 (0.48) | CIB1CD274PDCD1EPS15KLKB1 | |
| SCHEMBL24218647 | 0.95 | KLK5 (0.48) | CIB1CD274PDCD1EPS15KLKB1 | |
| SCHEMBL24218684 | 0.89 | PLAU (0.52) | CD274PDCD1EPS15KLKB1PLAU | |
| SCHEMBL24218681 | 0.89 | PLAU (0.52) | CD274PDCD1EPS15KLKB1PLAU | |
| SCHEMBL24218680 | 0.88 | KLKB1 (0.51) | CIB1CD274PDCD1KLKB1SLC6A3 | |
| SCHEMBL24218656 | 0.87 | KLKB1 (0.56) | CIB1CD274PDCD1KLKB1SLC6A3 | |
| SCHEMBL24218691 | 0.86 | CIB1 (0.52) | CIB1EPS15MC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | CIB1 4643/4885CD274 3229/4885PDCD1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.